Table of Contents
- ABOUT DATAMONITOR HEALTHCARE
- About the cardiovascular pharmaceutical analysis team
- CHAPTER 1 EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the disease market
- Related reports
- CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Definition of drug classes
- Current seven major market assessment
- The antihypertensives market segmented by class
- The antihypertensives market segmented by country
- Antihypertensive market landscape
- Historical influences on the market
- Strategic scope
- Consideration of market unmet needs
- Conflicting evidence from clinical trials and guideline alterations
- Paradigm shift in antihypertensive R&D
- Defining the unmet need in the antihypertensives market
- Beyond blood pressure reduction
- Improved diagnosis
- Improved blood pressure management
- Increased uptake of fixed-dose combination therapies
- Targeting global cardiovascular risk and organ damage
- Patient and primary care physician education
- Rest of World snapshot
- Current market assessment
- Future seven major market assessment
- Overview
- Market drivers and market restraints
- Key factors driving growth of the antihypertensives market
- Factors restraining growth of the antihypertensives market
- Forecast summary
- Key events summary
- CHAPTER 3 BRAND DYNAMICS
- Overview of the competitive landscape
- Angiotensin receptor blockers
- Class level events
- Blopress/Atacand (candesartan)
- Diovan/Co-Diovan (valsartan/valsartan + HCTZ)
- Exforge (valsartan+ amlodipine)
- Cozaar (losartan)/Hyzaar (losartan + HTCZ)
- Micardis (telmisartan)
- Benicar (olmesartan)
- Angiotensin converting enzyme inhibitors
- Lotrel (amlodipine + benazepril)
- Beta blockers
- Betaloc (metoprolol)
- Kredex (carvedilol)
- Calcium channel blockers
- Diuretics
- Renin inhibitors
- Tekturna/Rasilez (aliskiren)
- BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
- APPENDIX A: MARKET ASSUMPTIONS
- New product launches
- Patent expiries
- Data definitions, limitations and assumptions
- Standard units
- Japanese market data
- Derivation of sales forecasts and pricing trends
- Forecast methodology
- APPENDIX B
- Contributing experts
- Report methodology
- About Datamonitor
- About Datamonitor Healthcare
- About the Disease analysis team
- Disclaimer
- List of Tables
- Table 1: Antihypertensive sales in the seven major markets by class,
2006-07
- Table 2: Sales of antihypertensives across the seven major markets by
country, 2007
- Table 3: Sales of the leading branded drugs for hypertension in the seven
major markets, 2007
- Table 4: Leading branded drug sales for hypertension in the seven major
markets and Rest of World, 2007
- Table 5: Forecast sales growth of hypertension drugs by class in the
seven major markets, 2007-17
- Table 6: Forecast sales of antihypertensives in the seven major markets,
2007-2017
- Table 7: Leading angiotensin receptor blockers sales($m) for
hypertension in the seven major markets, 2007-2017
- Table 8: Leading angiotensin receptor blockers single pill combinations
sales ($m) for hypertension in the seven major markets,2007-2017
- Table 9: Blopress/Atacand: key facts
- Table 10: Sales forecast ($m) for Blopress for hypertension in the seven
major markets, 2007-2017
- Table 11: Sales forecast ($m) for Atacand for hypertension in the seven
major markets, 2007-2017
- Table 12: Diovan: key facts
- Table 13: Sales forecast ($m) for Diovan for hypertension in the seven
major markets, 2007-2017
- Table 14: Sales forecast ($m) for Co-Diovan for hypertension in the seven
major markets, 2007-17
- Table 15: Key facts: Cozaar
- Table 16: Sales forecast ($m) for Cozaar for hypertension in the seven
major markets, 2007-2017
- Table 17: Sales forecast ($m) for Hyzaar for hypertension in the seven
major markets, 2007-2017
- Table 18: Micardis: key facts
- Table 19: Sales forecast ($m) for Micardis for hypertension in the seven
major markets, 2007-2017
- Table 20: Benicar: key facts
- Table 21: Sales forecast ($m) for Benicar for hypertension in the seven
major markets, 2007-2017
- Table 22: Leading angiotensin converting enzyme inhibitors sales ($m) for
hypertension in the 7 MM seven major markets,2007-2017
- Table 23: Leading beta-blockers sales ($m) for hypertension in the seven
major markets, 2007-2017
- Table 24: Betaloc/Toprol-XL: key facts
- Table 25: Sales forecast ($m) for Betaloc for hypertension in the seven
major markets, 2007-2017
- Table 26: Kredex/Coreg: key facts
- Table 27: Leading calcium-channel blockers sales ($m)for hypertension in
the seven major markets, 2007-2017
- Table 28: Norvasc: key facts
- Table 29: Datamonitor' s launch dates for hypertension products in the 5 EU
and US, 2008-2017
- Table 30: Patent expiry dates used in forecasting antihypertensive sales
in the seven major markets, 2007-2017
- List of Figures
- Figure 1: Antihypertensive market share by class in the seven major
markets, 2004-07
- Figure 2: Growth in the antihypertensives market by country, 2004-07
- Figure 3: Antihypertensive sales in the US, 5 EU and Japan, 2004-07
- Figure 4: Overall antihypertensive sales by country, 2006-07
- Figure 5: Key events impacting the hypertension market,2004-08
- Figure 6: Sales of antihypertensives by market type,2007
- Figure 7: Global hypertension sales growth by market segment, 2004-07
- Figure 8: Comparison of leading branded drug growth for hypertension in
the seven major markets and Rest of World*, 2006-07
- Figure 9: Forecast sales of antihypertensive drugs by class and value in
the seven major markets ($ bn), 2007-2017
- Figure 10: Forecast sales of antihypertensive drugs by class and volume
in the seven major markets, 2007-2017
- Figure 11: Market share of antihypertensives by class,2007 and 2017
- Figure 12: Impact of key events on the antihypertensive market, 2007-2017
- Figure 13: Market share of leading brands, 2007 and 2017
- Figure 14: Forecast sales of angiotensin receptor blockers, 2007-2017
- Figure 15: Hypertension-specific sales ($m) forecast for Blopress in the
seven major markets, 2007-2017
- Figure 16: Hypertension-specific sales ($m) forecast for Diovan in the
seven major markets, 2007-2017
- Figure 17: Hypertension-specific sales ($m) forecast for Cozaar in the
seven major markets, 2007-17
- Figure 18: Hypertension-specific sales ($m) forecast for Micardis in the
seven major markets, 2007-2017
- Figure 19: Hypertension-specific sales ($m) forecast for Benicar in the
seven major markets, 2007-2017
- Figure 20: Forecast sales of angiotensin converting enzyme inhibitors,
2007-17
- Figure 21: Hypertension-specific sales ($m) forecast for Lotrel in the
seven major markets, 2007-2017
- Figure 22: Forecast sales of beta blockers, 2007-17
- Figure 23: Hypertension-specific sales ($m) forecast for BETALOC in the
seven major markets, 2007-2017
- Figure 24: Hypertension-specific sales ($m) forecast for Kredex in the
seven major markets, 2007-2017
- Figure 25: Forecast sales of calcium channel blockers in the seven major
markets, 2007-2017
- Figure 26: Hypertension -specific sales ($m) forecast for Norvasc in the
US only, 2007-2017
|
Related Report
|
View Cart
